®
(pemetrexed) for non-small cell lung cancer, Spiriva ® (tiotropium bromide) for chronic obstructive pulmonary disorder (COPD), and Detrol ® (tolterodine) for overactive bladder. From previous experience, it has been noticed that these domestic 'branded' drugs obtained market approval prior to the originator drugs. As cancers, respiratory diseases and neurological conditions are prevalent both globally and in China 2 , the demand for new drugs that target these conditions is likely to be high. This high demand may drive local manufacturers to produce versions of new drugs that are not yet available on the Chinese market.
OBJECTIVES
The objective of this research is to evaluate the phenomenon of local manufacturing of drugs that are protected by international patents, explore the preferences on drug types, trends and the potential impact on these multinational pharmaceutical companies when launching their new drugs in China. 
METHODS

RESULTS
From the 2012 NDL, 260 drugs for neurological diseases, 106 drugs for cancers and 76 drugs for respiratory diseases were identified, whilst 95, 44 and 30 drugs respectively had the marketing years of both the import version and the local version available (Table 1) . Among these drugs, some imported ones were raw materials from the originators rather than the actual drugs (the manufactured end products). For these products, the comparison on the marketing years was between the imported raw materials and the local version of the manufactured end products ( Figure. As for imported raw materials versus local marketed drugs, 10 out of 19 neurology drugs had their local manufactured end products marketed before the raw materials from the originators were imported. The numbers were substantially less in the oncology and respiratory spaces, where the imported raw materials were mostly marketed before the locally manufactured end products became available (Figure 1 ).
Among the drugs of which the imported versions were marketed before the local counterparts, 12 neurology drugs, 2 oncology drugs and 1 respiratory drugs had no originator brands identified on the eMC and FDA websites -this is mostly likely due to the old age of these drugs. Of those with the originator brands identified, 24 out of 29 (83%) neurology drugs, 16 out of 24 (67%) oncology drugs, and 7 out of 11 (64%) respiratory drugs were manufactured by the originators. 
CONCLUSIONS
The low number of domestically manufactured drugs marketed before their imported counterparts in recent years suggests that the intellectual property (IP) issue in China might have improved since the 2009 health reform. There were a lot more neurology drugs available in 2012/2013 compared to the other two therapeutic areas. However, the current result suggests that in terms of percentage, the respiratory medicine was the most popular for inappropriate local manufacturing.
It is yet to be explored whether the observations were related to the costs of the originator drugs, the market demand, the difficulties in copying new molecules due to their complexity, or the high costs of manufacturing. The results obtained in this research may act as the basis for further exploration of IP issues in China.
One way for global pharmaceutical companies to bypass the undesirable local manufacturing is to form joint-ventures with these local manufacturers and to give them legal rights to domestically produce the end products. The high number of drug raw materials imported by originator companies supports this view. Of the imported drugs that were marketed before the local counterparts became available, most of them were originator drugs rather than generics made by manufacturers from other countries (e.g. India, South Korea). Without looking at the costs of these drugs at the time of launch, no conclusion can be drawn on whether the Chinese authorities at the time were simply aiming for the lowest cost.
Despite the observed decline of inappropriate drug manufacturing in China, with the recent revision of the IP laws that allow Chinese pharmaceutical companies to make generic copies of internationally patented drugs legally 1 , there is a high possibility that this number will increase in the near future.
For additional information, please contact: Ben.walton@gfk.com
